ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

SCN4A

sodium voltage-gated channel alpha subunit 4 · also Nav1.4, HYPP, SkM1, HYKPP · Sodium voltage-gated channel alpha subunits

14 programs in company-led studies act on SCN4A, from 13 companies: 4 in phase 3, 10 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
LidocaineruleKeenova Therapeuticsinhibitorphase 4632 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
RiluzoleruleSanofiinhibitorphase 462 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
Liposomal BupivacainerulePacira BioSciencesinhibitorphase 4391 running–ChEMBL
CarbamazepineruleGRIN Therapeuticsinhibitorphase 4211 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
chloroprocaineruleSinteticainhibitorphase 481 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
CarticaineruleLaboratoires Theainhibitorphase 411 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
LamotrigineruleGlaxoSmithKlineinhibitorphase 4610 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
RanolazineruleGilead Sciencesinhibitorphase 4260 runningSCN5AChEMBL
DronedaroneruleSanofiinhibitorphase 4180 runningCACNA1C, CACNA1D, CACNA1F, CACNA1S, HCN4, KCNJ2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
PrilocaineruleHaisco Pharmaceutical Groupinhibitorphase 420 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
RopivacainerulePainReforminhibitorphase 3174 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
QuinidineruleOtsukainhibitorphase 3171 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
PhenytoinruleViatrisinhibitorphase 3101 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL
rufinamideruleEisaiinhibitorphase 370 runningSCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN5A, SCN7A, SCN8A, SCN9AChEMBL

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.